Kevan L. Hartshorn, MD
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology

MD, Albert Einstein College of Medicine
MA, Williams College

Expertise includes: Innate immunity to respiratory infection; Neutrophil Biology; Influenza Virus; Gastrointestinal cancer.

Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Division of Graduate Medical Sciences

Active Staff Privileges
Boston Medical Center
Hematology & Medical Oncology

2010-2010 Boston Magazine: Selected as one of Boston's Top Doctors for 2010

A Randomized, Double-blind, Phase II Study of RAD001 10 mg/d plus Best Supportive Care versus Placebeo plus Best Supportive Care in the Treatment of Patients with Advanced Pancreatic Neuroendocri
04/04/2008 - 04/30/2011 (PI)
Novartis Pharmaceuticals Corporation

A randomized, double-blind, multi-center phase III study comparing everolimus (RAD001) plus best supportive care vs placebo, plus best best supportive care in patients with advanced gastric cance
03/16/2010 - 02/28/2011 (PI)
Novartis Pharmaceuticals Corporation

A Phase II, Multi-center, Open-label Trial to Evaluate the Efficacy and Safety of DAVANAT in Combination with 5-Fluorouracil when Administered as First Line Chemotherapy in Patients Advanced Bili
07/05/2007 - 07/04/2010 (PI)
Pro-Pharmaceuticals, Inc.

A Randomized, Open-Label Trial Comparing Two Avastin (bevacizumab)- Based Treatment Regimens for the First-Line Treatment of Metastatic Colorectal Cancer
05/17/2006 - 12/31/2009 (PI)
Genentech, Inc.

Enhancing Collectin Mediated Host Defense
04/01/1998 - 03/31/2003 (PI)
NIH/National Heart, Lung, and Blood Institute
5 R01 HL58910 04

An Open Label, Randomized, Controlled, Phase III, Multicenter, Clinical Trial of PN401 with HighDose 5-Fluoraouracil (5FU) vs. Gemcitabine for Treatment of Patients with Advanced Pancreatic Cancer
12/01/2001 - 11/30/2002 (PI)

11/17/2017 - 11/16/2020 (PI)

Enhancing Collectin Mediated Defense Against Influenza
07/01/2015 - 06/30/2019 (PI)

A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib of Placebo in Comb…
01/15/2015 - 01/31/2019 (PI)
Incyte Corporation

EL CENTRO: Engaging Latinos in the CENter of Cancer TReatment Options
09/01/2017 - 08/31/2018 (PI)
Dana Farber NIH-NCI

The JANUS 1 Study
08/26/2015 - 08/31/2018 (PI)
Incyte Corporation

Enhancing Collectin Medicated Defense Against Influenza
08/11/2011 - 06/30/2015 (PI)
5R01 HL069031-12

Development of Novel Immunotherapy for Influenza Virus Infection
09/01/2007 - 08/31/2013 (PI)
Mass General Hosp NIH-NIAID

Collectins and Innate Defense against Inhaled Pathogens
09/01/2009 - 08/31/2012 (PI)
Trustees of Boston University NIH-NIAID

Collectins and Innate Defense against Inhaled Pathogens
09/30/2009 - 08/31/2011 (PI)
Trustees of Boston University NIH-NIAID

Collectin-Mediated Defense Against Influenza
04/01/2006 - 08/10/2011 (PI)
5 R01 HL069031-09

Showing 10 of 13 results. Show All Results

Yr Title Project-Sub Proj Pubs
2018 Enhancing Collectin Mediated Defense Against Influenza 5R01HL069031-17 31
2016 Enhancing Collectin Mediated Defense Against Influenza 5R01HL069031-15 31
2014 Enhancing Collectin Mediated Defense Against Influenza 5R01HL069031-13 31
2013 Enhancing Collectin Mediated Defense Against Influenza 5R01HL069031-12 31
2012 Enhancing Collectin Mediated Defense Against Influenza 5R01HL069031-11 31
2011 Enhancing Collectin Mediated Defense Against Influenza 2R01HL069031-10 31
2010 Collectin-Mediated Defense Against Influenza 5R01HL069031-09 31
2009 Collectin-Mediated Defense Against Influenza 5R01HL069031-08 31
2008 Collectin-Mediated Defense Against Influenza 5R01HL069031-07 31
2007 Collectin-Mediated Defense Against Influenza 5R01HL069031-06 31
Showing 10 of 27 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Kumaradevan S, Lee SY, Richards S, Lyle C, Zhao Q, Tapan U, Jiangliu Y, Ghumman S, Walker J, Belghasem M, Arinze N, Kuhnen A, Weinberg J, Francis J, Hartshorn K, Kolachalama VB, Cifuentes D, Rahimi N, Chitalia VC. c-Cbl Expression Correlates with Human Colorectal Cancer Survival and Its Wnt/ß-Catenin Suppressor Function Is Regulated by Tyr371 Phosphorylation. Am J Pathol. 2018 Aug; 188(8):1921-1933.View Related Profiles. PMID: 30029779; DOI: 10.1016/j.ajpath.2018.05.007;.
  2. Hsieh IN, De Luna X, White MR, Hartshorn KL. The Role and Molecular Mechanism of Action of Surfactant Protein D in Innate Host Defense Against Influenza A Virus. Front Immunol. 2018; 9:1368. PMID: 29951070.
  3. van Eijk M, Rynkiewicz MJ, Khatri K, Leymarie N, Zaia J, White MR, Hartshorn KL, Cafarella TR, van Die I, Hessing M, Seaton BA, Haagsman HP. Lectin-mediated binding and sialoglycans of porcine surfactant protein D synergistically neutralize influenza A virus. J Biol Chem. 2018 Jul 06; 293(27):10646-10662.View Related Profiles. PMID: 29769321.
  4. White MR, Kandel R, Hsieh IN, De Luna X, Hartshorn KL. Critical role of C-terminal residues of the Alzheimer's associated ß-amyloid protein in mediating antiviral activity and modulating viral and bacterial interactions with neutrophils. PLoS One. 2018; 13(3):e0194001. PMID: 29547627.
  5. Nikolaidis NM, Noel JG, Pitstick LB, Gardner JC, Uehara Y, Wu H, Saito A, Lewnard KE, Liu H, White MR, Hartshorn KL, McCormack FX. Mitogenic stimulation accelerates influenza-induced mortality by increasing susceptibility of alveolar type II cells to infection. Proc Natl Acad Sci U S A. 2017 08 08; 114(32):E6613-E6622. PMID: 28739896.
  6. Tapan U, Lee SY, Weinberg J, Kolachalama VB, Francis J, Charlot M, Hartshorn K, Chitalia V. Racial differences in colorectal cancer survival at a safety net hospital. Cancer Epidemiol. 2017 08; 49:30-37.View Related Profiles. PMID: 28538169.
  7. De Luna X, Hartshorn KL. Influenza Casts a Lung Shadow. Am J Pathol. 2017 Apr; 187(4):697-699. PMID: 28222276; DOI: 10.1016/j.ajpath.2017.01.007;.
  8. Elias R, Karantanos T, Sira E, Hartshorn KL. Immunotherapy comes of age: Immune aging & checkpoint inhibitors. J Geriatr Oncol. 2017 May; 8(3):229-235.View Related Profiles. PMID: 28223073; DOI: 10.1016/j.jgo.2017.02.001;.
  9. Chua MM, Ortega CE, Sheikh A, Lee M, Abdul-Rassoul H, Hartshorn KL, Dominguez I. CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target. Pharmaceuticals (Basel). 2017 Jan 28; 10(1).View Related Profiles. PMID: 28134850; DOI: 10.3390/ph10010018;.
  10. Phull P, Quillen K, Hartshorn KL. Acute Oxaliplatin-induced Hemolytic Anemia, Thrombocytopenia, and Renal Failure: Case Report and a Literature Review. Clin Colorectal Cancer. 2016 Nov 23.View Related Profiles. PMID: 27989485; DOI: 10.1016/j.clcc.2016.11.005;.
Showing 10 of 162 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 162 publications over 34 distinct years, with a maximum of 11 publications in 2012

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Gastrointestinal cancer
Innate Immunity
Geriatric Oncology
Gastrointestinal Oncology
Respiratory viruses
Contact for Mentoring:

650 Albany St Evans Biomed Research Ctr
Boston MA 02118
Google Map

Hartshorn's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department